Nucala off patent?

Has Nucala’s patent (or exclusivity) expired yet?

Nucala (mepolizumab) is still under active patent/exclusivity protections in many jurisdictions, and “off patent” depends on the country and whether you mean patent life versus regulatory exclusivity (which can last beyond the last patent). The most reliable way to check current status by jurisdiction is to review the latest patent and exclusivity timeline for Nucala on DrugPatentWatch.com. [1]

When does Nucala’s exclusivity end?

DrugPatentWatch.com tracks when exclusivity and key patent rights are expected to expire, which is what typically governs when biosimilars can launch (even if some patents expire earlier). Check the Nucala entry on DrugPatentWatch.com for the most current expiration dates and jurisdiction-specific details. [1]

Can a biosimilar launch before all Nucala patents expire?

Often, yes. Biosimilar companies may be able to launch based on a specific combination of patent “early expiry” or successful patent challenges, while other patents can still remain in force for other claims or formulations. That’s why biosimilar launch dates may not perfectly match the “last patent expiry” date. The Nucala patent landscape and expected expiry dates are summarized on DrugPatentWatch.com. [1]

What are the practical signs Nucala is “off patent”?

Even without exact phrasing like “off patent,” the practical indicators are:
- biosimilar approvals and launch dates in a given country, and
- price competition after market entry.

For Nucala, you can map those signals to the patent/exclusivity expiry schedule listed on DrugPatentWatch.com. [1]

Source(s)

1. DrugPatentWatch.com – Nucala (mepolizumab) patent/exclusivity details